



Zorginstituut Nederland



| Van goede zorg verzekerd |



Zorginstituut Nederland

Experiences with Managed Entry Arrangements Examples from NL

Wim Goettsch*
Advisor International Affairs and
Academia

Milan, November 9 2015

| Van goede zorg verzekerd |



Topics

- What are Managed Entry Arrangements
- Examples from the Netherlands
- Learning and follow-up

3



What is a managed entry agreement (MEA)

- A Managed Entry Agreement is an arrangement between a manufacturer and payer/provider that enables access to (coverage/reimbursement of) a health technology subject to specified conditions. These arrangements can use a variety of mechanisms to address uncertainty about the performance of technologies or to manage the adoption of technologies in order to maximize effective their use, or limit their budget impact*.
- What types of MEAs#:
 1. Managing budget impacts (caps, volume deals etc)
 2. Managing uncertainty (coverage with evidence development)
 3. Managing utilization to optimize performance (limitation of technology diffusion to appropriately trained practitioners)

*Carlson JJ et al.. Health Policy. 2010;96:179-190.
*Klump et al. International Journal of Technology Assessment in Health Care, 27:1 (2011), 77-83.

4



Focus on Coverage with Evidence and Managed entry (expensive in-hospital drugs)


- 2006-2011: system of coverage with evidence development for expensive medicines in hospitals
- Approximately 5-10 new drugs or indications per year
- Evidence was collected in indication-based patient registries (observational data – comparative effectiveness research)
 - Appropriate use of care in daily practice
 - Cost-effectiveness of real world data

5



Process of CER request and guidance provided

- Guidelines on pharmacoeconomics and outcomes research by ZIN, including also VOI as starting point for preparation outcomes research
- Proposals send to ZIN for evaluation
 - Scientific advice
 - Preliminary meeting on dossier contents
 - Submission of official file



Conditional reimbursement (outcomes research; 4 years)

6



Examples

- oncology:
 - trastuzumab, avastin, rituximab
- rheumatology
 - rituximab, abatacept, tocilizumab
- eye diseases
 - ranibizumab
- (ultra)orphans
 - alglucosidase alfa, galactosidase alfa en beta

7



General challenges of CER studies

- VOI was not adequately used as starting point
 - Resulting in too large studies
- Extra tasks for health care professionals
- Small sample sizes
- Lack of consistency in data collection and missing data
- Differences in patient characteristics between treatment groups
- QoL measured per health state not for different treatment groups



8



Outcomes of reassessment based on CER results

Infliximab in ulcerative colitis and plaque psoriasis

- Remains reimbursed (*not possible to organize managed entry*)

Ranibizumab in AMD

- Stop reimbursement by 2015 unless... (*not taken over by Minister!*)

Alfa-glucosidase in Pompe and Alfa-galactosidase in Fabry

- Remove from reimbursement but fund under special conditions (*not taken over by Minister!*)

DIFFICULT TO STOP or LIMIT REIMBURSEMENT!!!!

Omalizumab in persistent severe allergic asthma

- No cure-no pay deal (2 year try-out)

9

Conclusions

- New outcomes based deals should be further explored
- We must try to stay away from previous mistakes. **NO MANAGED ENTRY WITHOUT MANAGED EXIT!**
- All stakeholders should shoulder a tangible responsibility
- And wear appropriate protection

